1314705-20-8Relevant articles and documents
Purification method of everolimus
-
Paragraph 0087; 0088; 0089, (2019/01/24)
The invention provides a purification method of everolimus. According to the method, derivatization, separation and hydrolysis are carried out on everolimus, the treated everolimus has greatly reducedimpurity rapamycin content, and further by means of one-time preparation of liquid phase for purification, a high purity product with high yield can be obtained, thereby reducing the industrial costof the purification steps. The invention also further provides a preparation method of everolimus. The method has the advantages of high yield and simple operation, and is suitable for industrial production.
Pimecrolimus ivermectin intermediate and degrade the impurity of the preparation method
-
Paragraph 0033; 0034, (2017/08/25)
The invention discloses methods for preparing everolimus intermediates and everolimus degradation impurities, and particularly relates to methods for synthesizing the immunosuppressant everolimus intermediates and the everolimus degradation impurities rep
RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME
-
Paragraph 0085, (2015/02/25)
A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.
